Skip to search formSkip to main contentSkip to account menu

tezacitabine

Known as: 2'-Deoxy-2'-(fluoromethylene)cytidine, Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-, (E)-2'-deoxy-2'-(fluoromethylene)cytidine 
A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Antineoplastic AgentsDeoxycytidineEnzyme InhibitorsRadiation-Sensitizing Agents

Narrower (1)

MDL 101731
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A density functional theory study on the kinetics and thermodynamics of N-glycosidic bond cleavage in 5-substituted 2'-deoxycytidines.
B3LYP/6-311+G(2d,p)//B3LYP/6-31+G(d) density functional theory calculations were employed to explore the kinetics and… 
2002
2002
Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response.
(E)-2'-deoxy-2'-(fluoromethylene)cytidine (FMdC) is a new analog of deoxycytidine with promising anticancer activity. We… 
Highly Cited
1999
Highly Cited
1999
Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography.
Simultaneous determination of ribonucleoside and deoxyribonucleoside triphosphates in cells by HPLC is an analytical challenge… 
1999
1999
Potentiation of cytotoxicity and radiosensitization of (E)‐2‐deoxy‐2′‐(fluoromethylene) cytidine by pentoxifylline In vitro
(E)‐2′‐deoxy‐2′‐(fluoromethylene) cytidine (FMdC), a novel inhibitor of ribonucleotide‐diphosphate reductase, has been shown to… 
1998
1998
Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene) cytidine: on a daily × 5-day schedule
Abstract(E)-2′-deoxy-2′-(fluoromethylene)cytidine (FMdC), one of the most potent inhibitors of ribonucleoside diphosphate… 
1997
1997
Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731).
The effect of the antitumor drug MDL 101,731 [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] on tumor growth and on steady-state… 
1997
1997
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice.
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluromethylene) cytidine (FMdC), a novel inhibitor of ribonucleotide… 
1995
1995
Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase.
Daily oral or intravenous administration of the ribonucleoside diphosphate reductase inhibitor, (E)-2'-deoxy-2'-(fluoromethylene… 
1994
1994
Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase.
(E)-2'-Deoxy-2'-(fluoromethylene)cytidine (MDL 101,731) is a mechanism-based inhibitor of ribonucleoside diphosphate reductase (J… 
1994
1994
Effect of 2'-deoxy-2'-(fluoromethylene) cytidine on the ultraviolet and X-ray sensitivity of HeLa cells.
The effects of treatment of HeLa cells with the antitumor nucleoside analog 2'-deoxy-2'-(fluoromethylene) cytidine (FMdC) on… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)